Evidence
Fact check: what the studies can tell us
The short version
FDA staff reviewed 12 proposed uses in 2024 and judged the evidence insufficient to establish effectiveness for every one.
That does not mean every study found nothing. It means the full body of evidence did not give FDA reviewers a reliable answer that the peptide works for those uses.
Sepsis: the larger trial changed the picture
Sepsis is a life-threatening reaction to an infection. It is treated in hospital, and these studies were done on hospital patients.
An earlier study of 361 hospital patients suggested fewer deaths; a larger, more rigorous trial published in 2025 enrolled 1,106 patients and found about 23 deaths per 100 with thymosin alpha-1 versus about 24 per 100 with a dummy shot.
The 2025 sepsis trial listed the company that makes the medicine it used as a supporter, and several of its authors had received grants or fees from that company.
A 2025 review added up the results of 11 sepsis trials. Taken together, they seemed to show fewer deaths. But when the review counted only the better-run trials, or only trials run at several hospitals, that benefit was no longer clear.
Hepatitis: older trials did not settle it
In a U.S. trial from the 1990s, 97 people with hepatitis B got either thymosin alpha-1 or a placebo, a dummy treatment with no medicine in it. Those on the drug did not do clearly better.
A trial enrolled 552 people with hepatitis C; adding the peptide to an older treatment failed to raise the cure rate.
A respiratory illness and cancer: no firm benefit
A 2023 review of 9 COVID-19 studies covering more than 5,000 hospital patients found no reduction in deaths.
A 2011 review of cancer studies saw a hint of fewer deaths, but it could not prove that people lived longer. In 2024, FDA reviewers found no clear benefit for the cancers they examined.
The practical reading
A theory about how a drug might act in the body is not proof that it helps patients. A small hopeful study is not the same as a repeated result. The best question is not “Has it been studied?” but “What happened in the strongest study for my exact condition?”